Enzyvant gains double fast-track for rare disease drugSwitzerland-based biopharma start-up Enzyvant has gained a double fast track status from the FDA for its new rare Share XEnzyvant gains double fast-track for rare disease drughttps://pharmaphorum.com/news/enzyvant-gains-double-fast-track-rare-disease-drug/
